Clinical efficacy and safety of mecapegfilgrastim in small cell lung cancer as primary prophylaxis of neutropenia post chemotherapy: a retrospective analysis

doi:10.21037/apm-21-1400

	Clinical efficacy and safety of mecapegfilgrastim in small cell lung cancer as primary prophylaxis of neutropenia post chemotherapy: a retrospective analysis
	Gu, Xiaodong 1,2,3; Zhang, Yiping 2,3
刊名	ANNALS OF PALLIATIVE MEDICINE
	2021-07-01
卷号	10
关键词	Pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) mecapegfilgrastim primary prophylaxis chemotherapy neutropenia
ISSN号	2224-5820
DOI	10.21037/apm-21-1400
通讯作者	Zhang, Yiping(zyp@medmail.com.cn)
英文摘要	Background: Neutropenia is the most common adverse reaction seen in small cell lung cancer after chemotherapy. Febrile neutropenia (FN) leads to an increase in hospitalizations and may even be life-threatening. This paper aims to investigate the efficacy and adverse reactions of mecapegfilgrastim in the primary prophylaxis of neutropenia in patients with small cell lung cancer after receiving intermediate risk chemotherapy with at least one patient risk factor. Methods: The clinical records of 106 patients with small cell lung cancer admitted to Zhejiang Cancer Hospital from June 2019 to January 2021 were retrospectively analyzed. Patients were divided into a mecapegfilgrastim [pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF)] group and control group, each with 53 patients. The mecapegfilgrastim group received subcutaneous injection of mecapegfilgrastim 24 hours after the first cycle of chemotherapy, while the control group did not receive this. The Chi-square (chi(2)) test or Fisher exact test were used to compare the incidence of neutropenia, FN, and the proportion of patients administrated with full dose chemotherapy in the two groups after the first cycle of chemotherapy. Data on adverse events after mecapegfilgrastim were also collected. Results: After the first cycle of chemotherapy, the incidence of neutropenia in the mecapegfilgrastim group was significantly lower than that in the control group (P=0.001) and the incidence of FN in the mecapegfilgrastim group was lower than that in the control group (P=0.118). The proportion of patients administrated with full-dose chemotherapy in the mecapegfilgrastim group was significantly higher than that in the control group (P=0.001). The main adverse reactions to mecapegfilgrastim were muscle pain, fever, and fatigue. Conclusions: After receiving intermediate risk chemotherapy, the incidence of neutropenia was significantly reduced by the primary prophylaxis of mecapegfilgrastim in patients with small cell lung cancer. The adverse events of mecapegfilgrastim were mild and tolerable, and included muscle pain, fever, and fatigue.
WOS关键词	PHASE-III ; MULTICENTER
WOS研究方向	Health Care Sciences & Services
语种	英语
出版者	AME PUBL CO
WOS记录号	WOS:000691522100036
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/125215]
专题	中国科学院合肥物质科学研究院
通讯作者	Zhang, Yiping
作者单位	1.Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou, Peoples R China 2.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Thorac Med Oncol, 1 Banshan East St, Hangzhou 330022, Peoples R China 3.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Gu, Xiaodong,Zhang, Yiping. Clinical efficacy and safety of mecapegfilgrastim in small cell lung cancer as primary prophylaxis of neutropenia post chemotherapy: a retrospective analysis[J]. ANNALS OF PALLIATIVE MEDICINE,2021,10.
APA	Gu, Xiaodong,&Zhang, Yiping.(2021).Clinical efficacy and safety of mecapegfilgrastim in small cell lung cancer as primary prophylaxis of neutropenia post chemotherapy: a retrospective analysis.ANNALS OF PALLIATIVE MEDICINE,10.
MLA	Gu, Xiaodong,et al."Clinical efficacy and safety of mecapegfilgrastim in small cell lung cancer as primary prophylaxis of neutropenia post chemotherapy: a retrospective analysis".ANNALS OF PALLIATIVE MEDICINE 10(2021).